Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES CREADES IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM’S MAIN MARKET
Mandate

VINGE ADVISES CREADES IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM’S MAIN MARKET

December 05, 2013

Creades AB (publ) (NASDAQ OMX First North) has been approved for listing on NASDAQ OMX’s main market. The first day of trading was 6 December 2013.

Vinge’s team primarily consisted of partner Erik Sjöman and associates Jo-Anna Nordström, Christian Lindhé and Rikard Lindahl. Associates Maria Schultzberg and Maria Doeser advised in relation to tax matters.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026